IL221901D0 - Morpholinylquinazolines - Google Patents

Morpholinylquinazolines

Info

Publication number
IL221901D0
IL221901D0 IL22190112A IL22190112A IL221901D0 IL 221901 D0 IL221901 D0 IL 221901D0 IL 22190112 A IL22190112 A IL 22190112A IL 22190112 A IL22190112 A IL 22190112A IL 221901 D0 IL221901 D0 IL 221901D0
Authority
IL
Israel
Prior art keywords
morpholinylquinazolines
Prior art date
Application number
IL22190112A
Other versions
IL221901A (en
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE102010011493 priority Critical
Priority to PCT/EP2011/000767 priority patent/WO2011113512A1/en
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of IL221901D0 publication Critical patent/IL221901D0/en
Publication of IL221901A publication Critical patent/IL221901A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
IL221901A 2010-03-16 2012-09-11 Morpholinylquinazolines IL221901A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE102010011493 2010-03-16
PCT/EP2011/000767 WO2011113512A1 (en) 2010-03-16 2011-02-17 Morpholinylquinazolines

Publications (2)

Publication Number Publication Date
IL221901D0 true IL221901D0 (en) 2012-12-02
IL221901A IL221901A (en) 2016-04-21

Family

ID=43828057

Family Applications (1)

Application Number Title Priority Date Filing Date
IL221901A IL221901A (en) 2010-03-16 2012-09-11 Morpholinylquinazolines

Country Status (16)

Country Link
US (1) US9126952B2 (en)
EP (1) EP2547664B1 (en)
JP (1) JP2013522249A (en)
KR (1) KR20130017086A (en)
CN (1) CN102803227B (en)
AR (1) AR080757A1 (en)
AU (1) AU2011229542A1 (en)
BR (1) BR112012022868A2 (en)
CA (1) CA2793299A1 (en)
EA (1) EA201201289A1 (en)
ES (1) ES2586227T3 (en)
IL (1) IL221901A (en)
MX (1) MX2012010557A (en)
SG (1) SG183855A1 (en)
WO (1) WO2011113512A1 (en)
ZA (1) ZA201207727B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011118830A1 (en) * 2011-11-18 2013-05-23 Merck Patent Gmbh Morpholinylbenzotriazine
WO2013163190A1 (en) 2012-04-24 2013-10-31 Vertex Pharmaceutical Incorporated Dna-pk inhibitors
ES2711839T3 (en) 2013-03-12 2019-05-07 Vertex Pharma DNA-PK inhibitors
UY35464A (en) 2013-03-15 2014-10-31 Araxes Pharma Llc KRAS G12C covalent inhibitors.
DE102013008118A1 (en) 2013-05-11 2014-11-13 Merck Patent Gmbh arylchinazoline
CN106488910A (en) * 2013-10-10 2017-03-08 亚瑞克西斯制药公司 Inhibitors of kras g12c
TWI659021B (en) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Inhibitors of kras g12c
AU2014337154B2 (en) 2013-10-17 2018-06-28 Vertex Pharmaceuticals Incorporated Co-crystals of (s)-N-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as DNA-PK inhibitors
TW201625305A (en) 2014-09-18 2016-07-16 Araxes Pharma Llc Combination therapy for the treatment of cancer
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
EP3280708A1 (en) 2015-04-10 2018-02-14 Araxes Pharma LLC Substituted quinazoline compounds and methods of use thereof
WO2016168540A1 (en) 2015-04-15 2016-10-20 Araxes Pharma Llc Fused-tricyclic inhibitors of kras and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
JP2018533939A (en) 2015-10-19 2018-11-22 アラクセス ファーマ エルエルシー Method for screening for inhibitors of RAS
EP3377481A1 (en) 2015-11-16 2018-09-26 Araxes Pharma LLC 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) * 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
CA3049259A1 (en) * 2017-10-31 2019-05-09 Southern Research Institute Substituted quinazoline sulfonamides as thioredoxin interacting protein (txnip) inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69111077T2 (en) 1990-11-06 1995-11-02 Pfizer quinazoline derivatives to improve the anti-tumor effect.
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
JP2994165B2 (en) * 1992-06-26 1999-12-27 ゼネカ・リミテッド Quinazoline derivatives, pharmaceutical formulations for obtaining anticancer activity containing their production and the quinazoline derivative
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
AU4972900A (en) 1999-04-08 2000-11-14 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
WO2002020500A2 (en) * 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
CA2442742A1 (en) * 2001-02-21 2002-08-29 Mitsubishi Pharma Corporation Quinazoline derivatives
US20040006087A1 (en) * 2001-12-03 2004-01-08 Schering Corporation Method of treating cancer using FPT inhibitors and antineoplastic agents
PE02852006A1 (en) * 2004-03-30 2006-05-08 Aventis Pharma Inc Substituted pyridones as inhibitors of pol (adp-ribose) polymerase (PARP)
ES2288359B1 (en) 2005-07-08 2009-07-23 Consejo Superior Investigaciones Cientificas Coordinated control system for continuous extraction lines of virgin olive oil.
JP2009510044A (en) * 2005-09-29 2009-03-12 グラクソ グループ リミテッドGlaxo Group Limited Pyrazolo [3,4-b] pyridine compounds and their use as PDE4 inhibitors
DE102006012251A1 (en) * 2006-03-15 2007-11-08 Grünenthal GmbH Substituted 4-aminoquinazoline derivatives and their use for the preparation of medicaments
EP1903038A1 (en) * 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators
EP1995241B1 (en) * 2007-03-23 2010-03-17 ICAgen, Inc. Inhibitors of ion channels
WO2009013126A1 (en) * 2007-07-20 2009-01-29 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
WO2009020140A1 (en) * 2007-08-06 2009-02-12 Dainippon Sumitomo Pharma Co., Ltd. Adamantylurea derivative
KR20110046514A (en) * 2008-07-31 2011-05-04 제넨테크, 인크. Pyrimidine Compounds, Compositions and Methods of Use
AU2010336386B2 (en) * 2009-12-23 2016-01-21 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors

Also Published As

Publication number Publication date
US9126952B2 (en) 2015-09-08
ES2586227T3 (en) 2016-10-13
EP2547664B1 (en) 2016-05-04
MX2012010557A (en) 2012-10-05
AR080757A1 (en) 2012-05-09
KR20130017086A (en) 2013-02-19
EP2547664A1 (en) 2013-01-23
EA201201289A1 (en) 2013-08-30
CA2793299A1 (en) 2011-09-22
SG183855A1 (en) 2012-10-30
AU2011229542A1 (en) 2012-11-08
ZA201207727B (en) 2013-06-26
IL221901A (en) 2016-04-21
CN102803227B (en) 2016-01-20
JP2013522249A (en) 2013-06-13
WO2011113512A1 (en) 2011-09-22
BR112012022868A2 (en) 2018-06-05
CN102803227A (en) 2012-11-28
US20130012489A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
IL223783D0 (en) Pro-neurogenic compounds
AP3107A (en) 5-Alkynyl-pyrimidines
GB201008134D0 (en) Compounds
EP2566479A4 (en) Azaindazoles
GB201215746D0 (en) Rotocraft
PL2534132T3 (en) Substituted pyrrolidine-2-carboxamides
EP2547244A4 (en) Combination juicer-blender
GB201015949D0 (en) Compounds
GB201010196D0 (en) Methods
AP3607A (en) Substituted imidazopyridazines
HRP20181800T1 (en) Well
EP2622917A4 (en) Positioning
EP2640189A4 (en) 3-deutero-pomalidomide
GB201113558D0 (en) Kraftfahrzeugkarosserie mit strukturverstarkter vorderrahmenanbindung
ZA201207727B (en) Morpholinylquinazolines
GB201015079D0 (en) Novel use
GB201108084D0 (en) Subbuffer objects
HK1187908A1 (en) Imidazotriazinone compounds
HK1181747A1 (en) 1-hydroxyimino-3-phenyl-propanes 1--3--
HK1179966A1 (en) Tetrahydro-pyrido-pyrimidine derivatives --
GB201112400D0 (en) No details
HRP20160094T1 (en) Triazine-oxadiazoles
HK1176934A1 (en) Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes --[e]
GB201205984D0 (en) No details
EP2622916A4 (en) Positioning

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees